Li Junyi, Zhou Li, Ouyang Xinping, He Pingping
School of Nursing, Hengyang Medical College, University of South China, Hengyang, China.
Department of Pathology, Chongqing Public Health Medical Center, Southwest University Public Health Hospital, Chongqing, China.
Front Cardiovasc Med. 2021 Sep 9;8:701279. doi: 10.3389/fcvm.2021.701279. eCollection 2021.
Transcription factor-7-like-2 (TCF7L2), a vital member of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family, plays an important role in normal human physiological and pathological processes. TCF7L2 exhibits multiple anti-atherosclerotic effects through the activation of specific molecular mechanisms, including regulation of metabolic homeostasis, macrophage polarization, and neointimal hyperplasia. A single-nucleotide substitution of TCF7L2, rs7903146, is a genetic high-risk factor for type 2 diabetes and indicates susceptibility to cardiovascular disease as a link between metabolic disorders and atherosclerosis. In this review, we summarize the anti-atherosclerosis effect and novel mechanisms underlying the function of TCF7L2 to elucidate its potential as an anti-atherosclerosis biomarker and provide a novel therapeutic target for cardiovascular diseases.
转录因子7样蛋白2（TCF7L2）是T细胞因子/淋巴样增强因子（TCF/LEF）家族的重要成员，在人类正常生理和病理过程中发挥重要作用。TCF7L2通过激活特定分子机制表现出多种抗动脉粥样硬化作用，包括调节代谢稳态、巨噬细胞极化和内膜增生。TCF7L2的单核苷酸替换rs7903146是2型糖尿病的遗传高危因素，表明其作为代谢紊乱与动脉粥样硬化之间的联系易患心血管疾病。在本综述中，我们总结了TCF7L2的抗动脉粥样硬化作用及其功能的新机制，以阐明其作为抗动脉粥样硬化生物标志物的潜力，并为心血管疾病提供新的治疗靶点。
